Antifungal agents in the 1990s. Current status and future developments

Drugs

Volumn 53, Issue 4, 1997, Pages 539-549

  Kauffman, Carol A ^a,c   Carver, Peggy L ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DIFLUOROPHENYL) 1 [3 [2 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL]VINYL] 1,2,4 TRIAZOL 1 YL] 3 (1,2,4 TRIAZOL 1 YL) 2 PROPANOL; 4 [4 [4 [4 [[5 (2,4 DIFLUOROPHENYL)TETRAHYDRO 5 (1H 1,2,4 TRIAZOL 1 YLMETHYL)FURAN 3 YL]METHOXY]PHENYL] 1 PIPERAZINYL] PHENYL] 2,4 DIHYDRO 2 (1 ETHYL 2 HYDROXYPROPYL) 3H 1,2,4 TRIAZOLE 3 ONE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ECHINOCANDIN B; FLUCONAZOLE; FLUCYTOSINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; ITRACONAZOLE; KETOCONAZOLE; LIPID; NIKKOMYCIN Z; PNEUMOCANDIN DERIVATIVE; TERBINAFINE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIFUNGAL ACTIVITY; ANTIMICROBIAL THERAPY; ASPERGILLOSIS; CANDIDIASIS; CHILL; COCCIDIOIDOMYCOSIS; CONGENITAL MALFORMATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG RESISTANCE; DYSPNEA; FEVER; FUNGAL MENINGITIS; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; HYPOKALEMIA; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MAINTENANCE THERAPY; MYCOSIS; NAUSEA; NEPHROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; RASH; REVIEW; SOMNOLENCE; TASTE DISORDER;

ASPERGILLUS; FUNGI;

EID: 0030953570     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199753040-00001     Document Type: Review

References (109)

1. Kauffman CA. Role of azoles in antifungal therapy. Clin Infect Dis 1996; 22 Suppl. 2: S148-53
2. Kauffman CA, Carver PL. Use of azoles for systemic antifungal therapy. Adv Pharmacol 1997; 39: 143-89
3. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994; 330: 263-72
4. Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996; 22 Suppl. 2: S133-44
5. Ostro MJ, Cullis PR. Use of liposomes as injectable-drug delivery systems. Am J Hosp Pharm 189; 46: 1576-87
6. Balfour JA, Faulds D. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in superficial mycoses. Drugs 1992; 43: 259-84
7. Hector RF. Compounds active against cell walls of medically important fungi. Clin Microbiol Rev 1993; 6: 1-21
8. Bartizal K, Scott T, Abruzzo GK, et al. In vitro evaluation of the pneumocandin antifungal agent L-733560, a new water soluble hybrid of L-705589 and L-731373. Antimicrob Agents Chemother 1995; 39: 1070-6
9. Debono M, Gordee RS. Antibiotics that inhibit fungal cell wall development. Ann Rev Microbiol 1994; 48: 471-97
10. Wardle HM, Law D, Denning DW. In vitro activity of BMS-181184 compared with those of fluconazole and amphotericin B against various Candida spp. Antimicrob Agents Chemother 1996; 40: 2229-31
11. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12: 308-29
12. Janoff AS, Boni LT, Popescu MC, et al. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci USA 1988; 85: 6122-6
13. Kan VL, Bennett JE, Amantea MA, et al. Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers. J Infect Dis 1991; 164: 418-21
14. Lopez-Berestein G, Fainstein V, Hopfer R, et al. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis 1985; 151: 704-10
15. Adler-Moore JP, Proffitt RT. Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. J Liposome Res 1993; 3: 429-50
16. Meunier F, Prentice HG, Ringden O. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother 1991; 28 Suppl. B: 83-91
17. Ng TTC, Denning DW. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections: evaluation of United Kingdom compassionate use data. Arch Intern Med 1995; 155: 1093-8
18. Arning M, Heer-Sonderhoff AH, Wehmeier A, et al. Pulmonary toxicity during infusion of liposomal amphotericin B in two patients with acute leukemia. Eur J Clin Microbiol Infect Dis 1995; 14: 41-3
19. Anaissie EJ, White M, Uzun O, et al. Amphotericin B lipid complex (ABLC) versus amphotericin B for treatment of hematogenous and invasive candidiasis: a prospective, randomized, multicenter trial [abstract no. LM21]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep: San Francisco
20. Sharkey PK, Graybill JR, Johnson ES, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996; 22: 315-21
21. Leenders ACAP, Reiss P, Portegies P, et al. A randomized trial of liposomal-amphotericin B (AmBisome®) 4 mg/kg vs amphotericin B 0.7 mg/kg for cryptococcal meningitis in HIV-infected patients [abstract no. LM35]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep: New Orleans
22. Ringden O, Meunier F, Tollemar J, et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991; 28 Suppl. B: 73-82
23. Mills W, Chopra R, Linch DC, et al. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haematol 1994; 86: 754-60
24. Meunier F. Alternative modalities of administering amphotericin B: current issues. J Infect 1994; 28 Suppl. 1: 51-6
25. Ranchère JY, Latour JF, Fuhrmann C, et al. Amphotericin B intralipid formulation: stability and particle size. J Antimicrob Chemother 1996; 37: 1165-9
26. Joly V, Aubry P, Ndayiragide A, et al. Randomized comparison of amphotericin B deoxycholale dissolved in dextrose or intralipid for the treatment of AIDS-associated cryptococcal meningitis. Clin Infect Dis 1996; 23: 556-62
27. Smith DE, Van de Velde V, Woestenborghs R, et al. The pharmacokinetics of oral itraconazole in AIDS patients. J Pharm Pharmacol 1992; 44: 618-9
28. Kintzel PE, Rollins CJ, Yee WJ, et al. Low itraconazole serum concentrations following administration of itraconazole suspension to critically ill allogeneic bone marrow transplant recipients. Ann Pharmacother 1995; 29: 140-3
29. 2 blockers [abstract no. A36]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1994 Oct: Orlando (FL)
30. Dismukes WE, Bradsher RW, Cloud CG, et al. Itraconazole therapy for blastomycosis and histoplasmosis. Am J Med 1992; 93: 489-97
31. Wheat J, Hafner R, Korzun AH, et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. Am J Med 1995; 98: 336-42
32. Wheat LJ, Hafner R, Wulfsohn M, et al. Prevention of relapse of histoplasmosis with itraconazole in patients with acquired immunodeficiency syndrome. Ann Intern Med 1993; 118: 610-6
33. Kauffman CA. Old and new therapies for sporotrichosis. Clin Infect Dis 1995; 21: 981-5
34. Sharkey PK, Graybill JR, Rinaldi MG, et al. Itraconazole treatment of phaeohyphomycosis. J Am Acad Dermatol 1990; 23: 577-86
35. Denning DW, Lee JY, Hostetler JS, et al. NIAID mycoses study group multicenter trial of oral itraconazole therapy of invasive aspergillosis. Am J Med 1994; 97: 135-44
36. Dupont B. Itraconazole therapy in aspergillosis: study in 49 patients. J Am Acad Dermatol 1990; 23: 607-14
37. Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992; 362: 83-9
38. Saag M, van der Horst C, Cloud G, et al. Randomized double blind comparison of amphotericin B plus flucytosine to amphotericin B alone (Step 1) followed by a comparison of fluconazole to itraconazole (Step 2) in the treatment of cryptococcal meningitis in patients with AIDS: Pt 1 [abstract no. I217]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep: San Francisco
39. van Der Horst C, Saag M, Cloud G, et al. Randomized double blind comparison of amphotericin B plus flucytosine to amphotericin B alone (Step 1) followed by a comparison of fluconazole to itraconazole (Step 2) in the treatment of cryptococcal meningitis in patients with AIDS: Pt 2 [abstract no. I216]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep: San Francisco
40. Powderly WG, Saag MS, Cloud GA, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992; 326: 793-8
41. Saag MS, Cloud CG, Graybill JR, et al. Comparison of fluconazole vs itraconazole as maintenance therapy of AIDS-associated cryptococcal meningitis [abstract no. I218]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep: San Francisco
42. Larsen RA, Bozzette SA, Jones BE, et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994; 19: 741-5
43. Sangeorzan JA, Bradley SF, He X, et al. Epidemiology of oral candidiasis in HIV infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 1994; 97: 339-47
44. Koletar SL, Russell JA, Fass RJ, et al. Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1990; 34: 2267-8
45. Walsh TJ, DePauw B, Anaissie E, et al. Recent advances in the epidemiology, prevention, and treatment of invasive fungal infections in neutropenic patients. J Med Vet Mycol 1994; 32 Suppl. 1: 33-51
46. Laine L, Dretler RH, Conteas C, et al. Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS: a randomized trial. Ann Intern Med 1992; 117: 655-60
47. Sobel JD. Candidal vulvovaginitis. Clin Obstet Gynecol 1993; 36: 153-65
48. Lebech PE, Nielsen NC, Lundvall F, et al. Treatment of vaginal candidiasis with a single dose of fluconazole. Eur J Clin Microbiol Infect Dis 1988; 7: 364-7
49. Lee BE, Feinberg M, Abraham J, et al. Congenital malformations in an infant born to a woman treated with fluconazole. Ped Infect Dis J 1992; 11: 1062-4
50. Pursley TJ, Blomquist IK, Abraham J, et al. Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis 1996; 22: 336-40
51. Inman W, Pearce G, Wilton L. Safety of fluconazole in the treatment of vaginal candidiasis: a prescription-event monitoring study, with special reference to the outcome of pregnancy. Eur J Clin Pharmacol 1994; 46: 115-8
52. Jacobs LG, Skidmore EA, Freeman K, et al. Oral fluconazole compared with bladder irrigation with amphotericin B for treatment of fungal urinary tract infections in elderly patients. Clin Infect Dis 1996; 22: 30-5
53. Fisher JF, Newman CL, Sobel JD. Yeast in the urine: solution for a budding problem. Clin Infect Dis 1995; 20: 183-9
54. Leu H-S, Huang C-T. Clearance of funguria with short-course antifungal regimens: a prospective randomized, controlled study. Clin Infect Dis 1995; 20: 1152-7
55. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994; 331: 1325-30
56. Phillips P, Shafran S, Garber G, et al. Fluconazole versus amphotericin B for candidemia in non-neutropenic patients: a multi-center randomized trial [abstract no. LM20]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep: San Francisco
57. Anaissie EJ, Darouiche RO, Abi-Said D, et al. Management of invasive Candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996; 23: 964-72
58. Galgiani JN, Catanzaro A, Cloud GA, et al. Fluconazole therapy for coccidiodal meningitis. Ann Intern Med 1993; 119: 28-35
59. Tucker RM, Denning DW, Dupont B, et al. Itraconazole therapy for chronic coccidioidal meningitis. Ann Intern Med 1990; 112: 108-12
60. Dewsnup DH, Galgiani JN, Graybill JR, et al. Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann Intern Med 1996; 124: 305-10
61. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845-51
62. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. Clin Infect Dis 1995; 171: 1545-52
63. Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia: results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993; 118: 495-503
64. Schaffner A, Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis 1995; 172: 1035-41
65. Hitchcock CA, Pye GW, Oliver GP, et al. UK-109,496: a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Antifungal activity and selectivity in vitro [abstract no. F72]. 35th Interscicnce Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep: San Francisco
66. Barry AL, Brown SD. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Antimicrob Agents Chemother 1996; 40: 1948-9
67. Dupont B, Denning D, Lode H, et al. UK-109,496, a novel, wide spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in chronic invasive aspergillosis [abstract no. F81]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep: San Francisco
68. Denning D, Del Favero A, Gluckman E, et al. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in acute invasive aspergillosis [abstract no. F80]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep: San Francisco
69. de Wit S, Dupont B, Cartledge JD, et al. Pilot study of a new triazole derivative (D0870) in HIV patients with oral candidiasis [abstract no. 1225]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1994 Oct: Orlando (FL)
70. Cartledge JD, Denning D, Dupont B, et al. Treatment of fluconazole resistant oral candidiasis with D0870 in patients with AIDS [abstract no. M89]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1994 Oct: Orlando (FL)
71. Graybill J, Najvar L, Bocanegra R, et al. Treatment of murine pulmonary aspergillosis with SCH56592 [abstract no. F99]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996
72. Wheat J, Bick C, Connolly P, et al. Comparison of a new triazole, Schering 56592, with itraconazole and amphotericin B for treatment of murine histoplasmosis [abstract no. F101]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep: New Orleans
73. Hofmann H, Bräutigam M, Weidinger G, et al. Treatment of toenail onychomycosis: a randomized, double-blind study with terbinafine and griseofulvin. Arch Dermatol 1995; 131: 919-22
74. Hull PR, Vismer HF. Treatment of cutaneous sporotrichosis with terbinafine. Br J Dermatol 1992; 126 Suppl. 39: 51-5
75. Schmitt HJ, Bernard EM, Andrade J, et al. MIC and fungicidal activity of terbinafine against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 1988; 32: 780-1
76. Ryder NS. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol 1992; 126 Suppl. 39: 2-7
77. Jung EG, Haas PJ, Bräutigam M, et al. Systemic treatment of skin candidosis: a randomized comparison of terbinafine and ketoconazole. Mycoses 1994; 37: 361-5
78. Abruzzo GK, Flattery AM, Gill CJ, et al. Evaluation of water-soluble pneumocandin analogs L-733560, L-70589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 1995; 39: 1077-81
79. Gordee R, Farmer J, Flokowitsch J, et al. In vitro anti-fungal activity of LY303366, a new antifungal agent derived from echinocandin B [abstract no. 360]. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1993 Oct: New Orleans
80. Hector RF, Zimmer BL, Pappagianis D. Evaluation of nikkomycins X and Z in murine models of coccidioidomycosis, histoplasmosis, and blastomycosis. Antimicrob Agents Chemother 1990; 34: 587-93
81. Oakley KL, Moore CB, Denning DW. Activity of pradimicin BMS-181184 against Aspergillus sp. [abstract no. F180]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep: New Orleans
82. Polak-Wyss A. Protective effect of human granulocyte colony stimulating factor (hG-CSF) on Candida infections in normal and immunosuppressed mice. Mycoses 1991; 34: 109-18
83. Mayer P, Schutze E, Lam C, et al. Recombinant murine granulocyte-macrophage colony-stimulating factor augments neutrophil recovery and enhances resistance to infections in myelosuppressed mice. J Infect Dis 1991; 163: 584-90
84. Roilides E, Holmes A, Blake C, et al. Antifungal activity of elutriated human monocytes against Aspergillus fumigatus hyphae: enhancement by granulocyte-macrophage colony-stimulating factor and interferon-γ. J Infect Dis 1994; 170: 894-9
85. Bodey GP, Anaissie E, Gutterman J, et al. Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer. Clin Infect Dis 1993; 17: 705-7
86. Grauer ME, Bokemeyer C, Bautsch W, et al. Successful treatment of a Trichosporon beigelii septicemia in a granulocytopenic patient with amphotericin B and granulocyte colony-stimulating factor. Infection 1994; 22: 283-6
87. Bushelman SJ, Callen JP, Roth DN, et al. Disseminated Fusarium solani infection. J Am Acad Dermatol 1995; 32: 346-51
88. Clemons KV, Brummer E, Stevens DA. Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis. Antimicrob Agents Chemother 1994; 38: 460-4
89. Joly V, Saint-Julien L, Carbon C, et al. In vivo activity of interferon-γ in combination with amphotericin B in the treatment of experimental cryptococcosis. J Infect Dis 1994; 170: 1331-4
90. Bennett JE, Dismukes WE, Dumas RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979; 301: 126-31
91. Sugar AM. Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrob Agents Chemother 1995; 39: 1907-12
92. Voice RA, Bradley SF, Sangeorzan JA, et al. Chronic candidal meningitis: an uncommon manifestation of candidiasis. Clin Infect Dis 1994; 19: 60-6
93. Francis P, Walsh TJ. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis 1992; 15: 1003-18
94. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts-M27. Villanova (PA): NCCLS, 1996
95. Pfaller MA, Rinaldi MG. Antifungal susceptibility testing: current state of technology, limitations, and standardization. Infect Dis Clin North Am 1993; 7: 435-44
96. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39: 1-8
97. Odds FC. Resistance of yeasts to azole-derivative antifungals. J Antimicrob Chemother 1993; 31: 463-71
98. He X, Tiballi RN, Zarins LT, et al. Azole resistance in oropharyngeal Candida albicans strains isolated from patients with HIV infection. Antimicrob Agents Chemother 1994; 38: 2495-7
99. Anaissie EJ, Karyotakis NC, Hachem R, et al. Correlation between in vitro and in vivo activity of antifungal agents against Candida species. J Infect Dis 1994; 170: 384-9
100. Graybill JR, Najvar LK, Holmberg JD, et al. Fluconazole treatment of Candida albicans infection in mice: does in vitro susceptibility predict in vivo response? Antimicrob Agents Chemother 1995; 39: 2197-200
101. Ghannoum MA. Is antifungal susceptibility testing useful in guiding fluconazole therapy? Clin Infect Dis 1996; 22 Suppl. 2: S161-5
102. Rex JH, Pfaller MA, Barry AL, et al. Antifungal susceptibility testing of isolates from a randomized, multicentcr trial of fluconazole versus amphotericin B as treatment of non-neutropenic patients with candidemia. Antimicrob Agents Chemother 1995; 39: 40-4
103. White A, Goetz MB. Azole-resistant Candida albicans: report of two cases of resistance to fluconazole and review. Clin Infect Dis 1994; 19: 687-92
104. Bart-Delabesse E, Boiron P, Carlotti A, et al. Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazole. J Clin Microbiol 1993; 31: 2933-7
105. Price MF, LaRocco MT, Gentry LO. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother 1994; 38: 1422-4
106. Wingard JR, Merz WG, Rinaldi MG, et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325: 1274-7
107. Tiballi RN, Zarins LT, He X, et al. Susceptibility of Torulopsis glabrata: azole susceptibilities by microdilution colorimetric and macrodilution broth assays. J Clin Microbiol 1995; 33: 2612-5
108. Vanden Bossche H, Warnock DW, Dupont B, et al. Mechanisms and clinical impact of antifungal drug resistance. J Med Vet Mycol 1994; 32 Suppl. 1: 189-202
109. Parkinson T, Falconer DJ, Hitchcock CA. Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata. Antimicrob Agents Chemother 1995; 39: 1696-9